IXP

DRUG2 trials

Sponsors

Vertex Pharmaceuticals Incorporated

Conditions

Focal Segmental Glomerulosclerosis (FSGS)Renal Impairment

Phase 1

A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment

CompletedNCT05865171

Vertex Pharmaceuticals IncorporatedRenal Impairment

Start: 2023-06-12End: 2024-06-12Updated: 2024-07-12

Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment

CompletedNCT06529796

Vertex Pharmaceuticals IncorporatedFocal Segmental Glomerulosclerosis (FSGS)

Start: 2024-08-02End: 2024-12-20Updated: 2025-01-20